# Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney

> **NCT02613819** · PHASE2 · UNKNOWN · sponsor: **Trans Tasman Radiation Oncology Group** · enrollment: 71 (actual)

## Conditions studied

- Renal Cell Carcinoma

## Interventions

- **RADIATION:** SABR

## Key facts

- **NCT ID:** NCT02613819
- **Lead sponsor:** Trans Tasman Radiation Oncology Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-07
- **Primary completion:** 2025-04
- **Final completion:** 2025-04
- **Target enrollment:** 71 (ACTUAL)
- **Last updated:** 2022-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02613819

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02613819, "Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02613819. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*